The company maintains a robust liquidity position with a 3.53 current ratio, supported by a conservative debt-to-equity profile of 0.19 as of 2026Q1.
Organogenesis Holdings Inc. (ORGO) balance sheet — 10-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 |
|---|
| Total Current Assets | 200.3M | 362.19M | 285.94M | 225.04M | 222.61M | 226.98M | 174.34M | 125.6M | 71.13M | 294.44K | 1.44M |
| Cash & Short-Term Investments | 46.1M | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M | 84.39M | 60.17M | 21.29M | 125.89K | 1.04M |
| Cash Only | 46.1M | 93.68M | 135.57M | 104.34M | 102.48M | 113.93M | 84.39M | 60.17M | 21.29M | 125.89K | 1.04M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 100.94M | 217.45M | 109.86M | 82M | 89.45M | 82.46M | 56.8M | 39.36M | 34.08M | 0 | 0 |
| Days Sales Outstanding | 120.74 | 140.97 | 83.19 | 69.1 | 72.41 | 64.4 | 61.29 | 55.05 | 64.3 | - | - |
| Inventory | 29.28M | 29.63M | 26.22M | 28.25M | 24.78M | 25.02M | 27.8M | 22.92M | 13.32M | 0 | 0 |
| Days Inventory Outstanding | 78.26 | 78.63 | 82.68 | 96.85 | 86.13 | 79.97 | 116.2 | 110.14 | 70.66 | - | - |
| Other Current Assets | 23.99M | 21.43M | 5.67M | 1.19M | 5.1M | 711K | 584K | 1.1M | 353K | 0 | 0 |
| Total Non-Current Assets | 206.14M | 236.54M | 211.94M | 234.98M | 226.75M | 216.28M | 115.87M | 95.09M | 92.55M | 312.5M | 310M |
| Property, Plant & Equipment | 151.44M | 159.46M | 126.24M | 156.35M | 145.66M | 128.3M | 55.79M | 47.18M | 39.62M | 0 | 0 |
| Fixed Asset Turnover | 3.15x | 3.53x | 3.82x | 2.77x | 3.10x | 3.64x | 6.06x | 5.53x | 4.88x | - | - |
| Goodwill | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M | 28.77M | 25.54M | 25.54M | 0 | 0 |
| Intangible Assets | 3M | 9.14M | 12.47M | 15.87M | 20.79M | 25.67M | 30.62M | 20.8M | 26.09M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 15.87M | 0 | 0 | 0 | 0 | 477K | 312.5M | 310M |
| Other Non-Current Assets | 22.93M | 9.2M | 5M | -9.88M | 1.52M | 1.54M | 670K | 1.44M | 579K | 0 | 0 |
| Total Assets | 406.45M | 598.73M | 497.89M | 460.02M | 449.36M | 443.26M | 290.22M | 220.69M | 163.68M | 312.79M | 311.44M |
| Asset Turnover | 0.90x | 0.94x | 0.97x | 0.94x | 1.00x | 1.05x | 1.17x | 1.18x | 1.18x | - | - |
| Asset Growth % | 33.88% | 20.25% | 8.23% | 2.37% | 1.38% | 52.73% | 31.51% | 34.83% | -47.67% | 0.44% | - |
| Total Current Liabilities | 56.96M | 100.12M | 77.48M | 80.51M | 75.02M | 82.7M | 68.22M | 59.89M | 66.39M | 3.93M | 478.36K |
| Accounts Payable | 29.29M | 31.95M | 28.91M | 30.72M | 32.33M | 29.34M | 23.38M | 28.39M | 19.16M | 19.05M | 0 |
| Days Payables Outstanding | 80.21 | 84.8 | 91.17 | 105.32 | 112.36 | 93.77 | 97.73 | 136.43 | 101.66 | 1.51K | - |
| Short-Term Debt | 0 | 18.64M | 0 | 5.49M | 4.54M | 2.66M | 16.67M | 0 | 2.54M | 100K | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30.41M | 0 | 0 |
| Other Current Liabilities | 18.36M | 49.53M | 25.29M | 22.17M | 9.33M | 29.44M | 21.58M | 25.58M | 22.22M | -30.01M | 0 |
| Current Ratio | 3.52x | 3.62x | 3.69x | 2.80x | 2.97x | 2.74x | 2.56x | 2.10x | 1.07x | 0.07x | 3.00x |
| Quick Ratio | 3.00x | 3.32x | 3.35x | 2.44x | 2.64x | 2.44x | 2.15x | 1.71x | 0.87x | 0.07x | 3.00x |
| Cash Conversion Cycle | 118.79 | 134.81 | 74.7 | 60.63 | 46.18 | 50.6 | 79.76 | 28.76 | 33.3 | - | - |
| Total Non-Current Liabilities | 61.35M | 64.69M | 35.09M | 100.85M | 108.67M | 119.22M | 80.19M | 105.21M | 50.25M | 10.85M | 10.85M |
| Long-Term Debt | 0 | 50.71M | 0 | 60.74M | 66.23M | 70.77M | 53.04M | 83.12M | 39.06M | 0 | 0 |
| Capital Lease Obligations | 213.29M | 63.49M | 34.2M | 38.9M | 41.31M | 46.89M | 11.44M | 14.43M | 10.15M | 12.39M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.71M | -49.51M | 894K | 1.21M | 1.12M | 1.56M | 15.71M | 7.66M | 903K | -1.54M | 10.85M |
| Total Liabilities | 118.31M | 164.81M | 112.57M | 181.36M | 183.69M | 201.92M | 148.41M | 165.1M | 116.64M | 14.78M | 11.33M |
| Total Debt | 66.95M | 132.84M | 43.31M | 119.35M | 123.79M | 132.3M | 84.77M | 100.61M | 59.26M | 17.86M | 0 |
| Net Debt | 20.85M | 39.16M | -92.26M | 15.01M | 21.31M | 18.37M | 377K | 40.43M | 37.97M | 17.73M | -1.04M |
| Debt / Equity | 0.23x | 0.31x | 0.11x | 0.43x | 0.47x | 0.55x | 0.60x | 1.81x | 1.26x | 0.06x | - |
| Debt / EBITDA | 75.14x | 1.60x | 2.75x | 3.32x | 3.07x | 1.49x | 2.43x | - | - | 17.24x | - |
| Net Debt / EBITDA | 23.40x | 0.47x | -5.86x | 0.42x | 0.53x | 0.21x | 0.01x | - | - | 17.11x | -0.14x |
| Interest Coverage | - | - | -0.82x | 5.75x | 11.10x | 9.72x | 2.57x | -3.29x | -4.97x | -0.82x | -0.04x |
| Total Equity | 288.13M | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M | 141.81M | 55.58M | 47.04M | 298.01M | 300.11M |
| Equity Growth % | 34.56% | 12.61% | 38.27% | 4.89% | 10.08% | 70.18% | 155.13% | 18.16% | -84.22% | -0.7% | - |
| Book Value per Share | 2.24 | 3.33 | 2.93 | 2.10 | 2.01 | 1.81 | 1.27 | 0.60 | 0.68 | 4.67 | 34.98 |
| Total Shareholders' Equity | 288.13M | 433.92M | 385.32M | 278.66M | 265.67M | 241.34M | 141.81M | 55.58M | 47.04M | 298.01M | 300.11M |
| Common Stock | 13K | 13K | 13K | 13K | 13K | 13K | 13K | 10K | 9K | 293.01M | 295.11M |
| Retained Earnings | -152.5M | -3.08M | -40.11M | -40.97M | -45.3M | -60.83M | -155.03M | -171.01M | -130.24M | -2.33M | -233.86K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -293.01M | -295.11M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying ORGO stock.
As of 2025, Organogenesis Holdings Inc. (ORGO) had total assets of $598.7M including $362.2M in current assets.
Organogenesis Holdings Inc. (ORGO) carries total debt of $132.8M, offset by $93.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Organogenesis Holdings Inc. (ORGO) has total shareholders' equity (book value) of $433.9M ($3.33 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Organogenesis Holdings Inc. (ORGO) reported a current ratio of 3.62x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Reimbursement and regulatory volatility
Metrics are mathematically derived from official filings.
Balance Sheet Stability Amid Volatility
As reported in financial statements, Organogenesis has maintained a relatively stable equity base, which stood at $381.3 million in 2026Q1, despite significant quarterly fluctuations in total assets and liabilities that suggest a business model highly sensitive to operational timing and external reimbursement-driven working capital cycles.
The company's balance sheet trajectory appears to be characterized by periodic expansion and contraction rather than steady growth, reflecting the inherent volatility of its regenerative medicine product cycles. Investors should monitor whether the recent asset contraction in 2026Q1 represents a structural shift or merely a temporary adjustment in inventory and receivables management.
Strategic Leverage Remains Conservatively Managed
Based on recent SEC filings, the company's debt-to-equity ratio of 0.19 in 2026Q1 indicates a conservative capital structure, which provides a necessary buffer against the regulatory and reimbursement uncertainties that frequently threaten the company's core revenue streams in the advanced wound care market.
The reduction in total debt from $132.8 million in 2025Q4 to $70.9 million in 2026Q1 suggests a proactive approach to deleveraging, likely intended to preserve financial flexibility. This low leverage profile appears to be a strategic necessity given the company's exposure to binary regulatory outcomes that could otherwise jeopardize its solvency.
Liquidity Buffers Support Operational Resilience
According to the provided balance sheet data, the company maintains a current ratio of 3.53 as of 2026Q1, which suggests a robust liquidity position capable of absorbing short-term shocks in cash flow resulting from the high-touch, cold-chain distribution requirements of its living cell therapy products.
The consistent maintenance of a current ratio well above 2.5 throughout the observed period indicates that management prioritizes liquidity to mitigate the risks associated with perishable inventory and reimbursement delays. This liquidity cushion appears essential for sustaining operations during periods of regulatory flux where revenue recognition may be deferred or challenged.
Hidden Risks in Asset Composition
As indicated by the financial data, the company's reliance on $157.8 million in net PPE as of 2026Q1 warrants further investigation, as this asset-heavy profile may be vulnerable to impairment if regulatory changes force a shift away from the company's current high-cost, specialized manufacturing and distribution model.
While the headline balance sheet appears healthy, the concentration of value in specialized manufacturing assets creates a potential trap if the underlying reimbursement economics for bioengineered tissues deteriorate. Investors should consider that these assets may lack significant alternative use value, potentially exposing the company to substantial write-downs in a less favorable regulatory environment.